K-ASSAY CRP

K991224 · Kamiya Biomedical Co. · DCK · May 14, 1999 · Immunology

Device Facts

• Record ID: K991224
• Device Name: K-ASSAY CRP
• Applicant: Kamiya Biomedical Co.
• Product Code: DCK · Immunology
• Decision Date: May 14, 1999
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5270
• Device Class: Class 2

Intended Use

The K-ASSAY CRP Assay is intended to be used for the quantitative determination of CRP in serum by immunoturbidimetric assay. Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissues. FOR IN VITRO DIAGNOSTIC USE.

Device Story

K-ASSAY CRP is an in vitro diagnostic reagent kit for quantitative measurement of C-reactive protein (CRP) in serum samples. It utilizes an immunoturbidimetric assay principle; antigen-antibody reaction between CRP in patient serum and anti-CRP antibodies causes turbidity proportional to CRP concentration. Used in clinical laboratory settings by trained technicians. Output is a quantitative CRP concentration value, used by physicians to assess tissue injury or inflammation. Benefits include rapid, automated assessment of inflammatory status.

Clinical Evidence

No clinical data provided; substantial equivalence is based on analytical performance characteristics typical of immunoturbidimetric assays for CRP.

Technological Characteristics

Immunoturbidimetric assay; utilizes anti-CRP antibodies for detection; liquid reagent format; designed for use on automated clinical chemistry analyzers; in vitro diagnostic use.

Indications for Use

Indicated for the quantitative determination of C-reactive protein (CRP) in human serum to aid in the evaluation of tissue injury. For in vitro diagnostic use by clinical laboratory professionals.

Regulatory Classification

Identification

A C-reactive protein immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the C-reactive protein in serum and other body fluids. Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissues.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird symbol, with three curved lines representing the bird's body and head. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular fashion around the bird symbol.

MAY 1 4 1999

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Mr. Colin Getty Official Correspondent Kamiya Biomedical Company 910 Industry Drive Seattle, Washington 98188

Re: K991224 Trade Name: K-ASSAY CRP Regulatory Class: II Product Code: DCK Dated: April 8, 1999 Received: April 12, 1999

Dear Mr. Getty:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{1}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely vours.

Steven Sutman

Steven I. Gutman, M.D. M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## INDICATIONS FOR USE STATEMENT

**510(k) Number (if known):** K991224

Device Name: K-ASSAY CRP.

## Indications For Use:

The K-ASSAY CRP Assay is intended to be used for the quantitative determination of CRP in serum by immunoturbidimetric assay. Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissues. FOR IN VITRO DIAGNOSTIC USE.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

| (Division Sign-Off) | |
|-----------------------------------------|--------|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | 991224 |

| Prescription Use<br>(Per 21 CFR 801.109) | OR | Over-The-Counter Use |
|------------------------------------------|----|----------------------|
|------------------------------------------|----|----------------------|

Optional Format 1-2-96)